Literature DB >> 22214782

Down syndrome and dementia: seizures and cognitive decline.

Ira T Lott1, Eric Doran, Vinh Q Nguyen, Anne Tournay, Nina Movsesyan, Daniel L Gillen.   

Abstract

The objective of this study was to determine the association of seizures and cognitive decline in adults with Down syndrome (DS) and Alzheimer's-type dementia. A retrospective data analysis was carried out following a controlled study of antioxidant supplementation for dementia in DS. Observations were made at baseline and every 6 months for 2 years. Seizure history was obtained from study records. The primary outcome measures comprised the performance-based Severe Impairment Battery (SIB) and Brief Praxis Test (BPT). Secondary outcome measures comprised the informant-based Dementia Questionnaire for Mentally Retarded Persons and Vineland Adaptive Behavior Scales. Because a large proportion of patients with seizures had such severe cognitive decline as to become untestable on the performance measures, time to "first inability to test" was measured. Adjustments were made for the potentially confounding co-variates of age, gender, APOE4 status, baseline cognitive impairment, years since dementia onset at baseline, and treatment assignment. The estimated odds ratio for the time to "first inability to test" on SIB comparing those with seizures to those without is 11.02 (95% CI: 1.59, 76.27), a ratio that is significantly different from 1 (p = 0.015). Similarly, we estimated an odds ratio of 9.02 (95% CI: 1.90, 42.85) on BPT, a ratio also significantly different than 1 (p = 0.006). Results from a secondary analysis of the informant measures showed significant decline related to seizures. We conclude that there is a strong association of seizures with cognitive decline in demented individuals with DS. Prospective studies exploring this relationship in DS are indicated.

Entities:  

Mesh:

Year:  2012        PMID: 22214782      PMCID: PMC3406603          DOI: 10.3233/JAD-2012-111613

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  55 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

2.  Adverse effects of phenytoin given for late-onset seizures in adults with Down syndrome.

Authors:  John A Tsiouris; Paul J Patti; Omer Tipu; Simhachalam Raguthu
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

3.  Behavioral phenotypes of genetic syndromes with intellectual disability: comparison of adaptive profiles.

Authors:  Santo Di Nuovo; Serafino Buono
Journal:  Psychiatry Res       Date:  2011-04-19       Impact factor: 3.222

4.  Comparison of rating scales for the diagnosis of dementia in adults with Down's syndrome.

Authors:  S Deb; J Braganza
Journal:  J Intellect Disabil Res       Date:  1999-10

5.  Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS).

Authors:  J C Möller; H M Hamer; W H Oertel; F Rosenow
Journal:  Seizure       Date:  2001-06       Impact factor: 3.184

6.  Age of seizure onset in adults with Down's syndrome.

Authors:  B K Puri; K W Ho; I Singh
Journal:  Int J Clin Pract       Date:  2001-09       Impact factor: 2.503

7.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

Authors:  Vee P Prasher; Adam Huxley; M S Haque
Journal:  Int J Geriatr Psychiatry       Date:  2002-03       Impact factor: 3.485

8.  EEG synchronization in mild cognitive impairment and Alzheimer's disease.

Authors:  C J Stam; Y van der Made; Y A L Pijnenburg; Ph Scheltens
Journal:  Acta Neurol Scand       Date:  2003-08       Impact factor: 3.209

9.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits.

Authors:  Jorge J Palop; Brian Jones; Lisa Kekonius; Jeannie Chin; Gui-Qiu Yu; Jacob Raber; Eliezer Masliah; Lennart Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-24       Impact factor: 11.205

10.  Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome.

Authors:  Christopher L Hunter; Ole Isacson; Matthew Nelson; Heather Bimonte-Nelson; Hyemyung Seo; Ling Lin; Kerstin Ford; Mark S Kindy; Ann-Charlotte Granholm
Journal:  Neurosci Res       Date:  2003-04       Impact factor: 3.304

View more
  32 in total

1.  Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial.

Authors:  Mary Sano; Paul S Aisen; Howard F Andrews; Wei-Yann Tsai; Florence Lai; Arthur J Dalton
Journal:  Neurology       Date:  2016-05-04       Impact factor: 9.910

2.  Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status.

Authors:  D M Walsh; E Doran; W Silverman; A Tournay; N Movsesyan; I T Lott
Journal:  J Intellect Disabil Res       Date:  2015-05-29

Review 3.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

4.  Relative Incidence of Seizures and Myoclonus in Alzheimer's Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia.

Authors:  Alexander J Beagle; Sonja M Darwish; Kamalini G Ranasinghe; Alice L La; Elissaios Karageorgiou; Keith A Vossel
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  ΔFosB Regulates Gene Expression and Cognitive Dysfunction in a Mouse Model of Alzheimer's Disease.

Authors:  Brian F Corbett; Jason C You; Xiaohong Zhang; Mark S Pyfer; Umberto Tosi; Daniel M Iascone; Iraklis Petrof; Anupam Hazra; Chia-Hsuan Fu; Gabriel S Stephens; Annie A Ashok; Suzan Aschmies; Lijuan Zhao; Eric J Nestler; Jeannie Chin
Journal:  Cell Rep       Date:  2017-07-11       Impact factor: 9.423

6.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

Review 7.  Pharmacotherapeutic Considerations for Individuals with Down Syndrome.

Authors:  Erik Hefti; Javier G Blanco
Journal:  Pharmacotherapy       Date:  2017-01-13       Impact factor: 4.705

Review 8.  Neurological phenotypes for Down syndrome across the life span.

Authors:  Ira T Lott
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

9.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

10.  Progressive myoclonus epilepsy in Down syndrome patients with dementia.

Authors:  Giuseppe d'Orsi; Luigi M Specchio
Journal:  J Neurol       Date:  2014-06-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.